Amicogen Reports Continued Losses, Financial Restatement, and Major Shareholder Change

Consolidated operating loss of KRW 8.57 billion and net loss of KRW 11.82 billion in H1 2025, widening losses YoY
Separate operating loss of KRW 5.48 billion and net loss of KRW 10.16 billion
Financial restatement: Recognized impairment loss of KRW 7.65 billion on subsidiary Puriogen, reducing equity
Debt ratio 132.4% and net borrowing ratio 90.8% (consolidated), worsening financial structure
Major shareholder change from Shin Yong-chul to Maga Investment Partners (Apr 17, 2025)\- Acceleration of loss of interest on convertible bonds, partial repayment expected
R&D expenditure of KRW 3.71 billion (17.71% of sales) continued